Bausch Health's OraPharma Celebrates 25 Years of ARESTIN® (minocycline HCl) Microspheres

Rhea-AI Summary

Bausch Health (NYSE:BHC) and OraPharma mark the 25th anniversary of ARESTIN (minocycline HCl) Microspheres, 1 mg, the only FDA‑approved locally applied antibiotic used adjunctively with scaling and root planing (SRP) for adult periodontitis. The product is supported by over two decades of clinical experience and recent commercial expansion into Canada and Puerto Rico.

The company emphasizes ongoing support for non‑surgical periodontal care and continued collaboration with the dental community.

News Market Reaction – BHC

-4.20%

10 alerts

-4.20% Session close to close

+6.6% Peak Tracked

-7.2% Trough Tracked

$2.35B Market Cap

0.7x Rel. Volume

In the Feb 19 session, BHC declined 4.20%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.6% during that session. Argus tracked a trough of -7.2% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The only FDA‑approved locally applied antibiotic used with scaling and root planing (SRP) marks a quarter‑century of clinical use

LAVAL, QC, Feb. 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its dental products business, OraPharma, today announced the 25th anniversary milestone of ARESTIN® (minocycline HCl) Microspheres, 1 mg, a locally administered antibiotic used as an adjunct to scaling and root planing (SRP) for the reduction of pocket depth in adult patients with periodontitis. ARESTIN is supported by over two decades of clinical experience and remains the only Food and Drug Administration (FDA) approved locally applied antibiotic for this use.

Dan Wu, Ph.D., Senior Director, Pharmaceutical Sciences & Technology, Bausch Health, and a member of the development team behind ARESTIN, reflected, "The 'why' behind developing ARESTIN began with recognizing that periodontal disease is a localized, chronic bacterial condition and that clinicians had no targeted way to help address it. There was a gap in treatment, and ARESTIN was developed to help fill that need by delivering antibiotic therapy directly into the periodontal pocket, using tiny microspheres that release the antibiotic gradually over time before naturally biodegrading."

Periodontal disease remains one of the most prevalent chronic oral health conditions globally, affecting more than one billion people¹. As part of comprehensive periodontal disease management, many dental professionals have incorporated ARESTIN with scaling and root planing (SRP).

"Reaching Arestin's 25-year milestone as the only FDA-approved locally applied antibiotic reflects our commitment to periodontal care," said Tom Stern, Vice President and General Manager of the OraPharma business, Bausch Health's dentistry division. "As we recognize this legacy, we are equally focused on the future—one defined by innovation and deeper collaboration with the dental community. Building on Arestin's impactful history, we continue to support non-surgical periodontal treatment for appropriate patients."

OraPharma continues to advance its commitment to periodontal health, including recent commercial expansion into Canada and Puerto Rico aimed at improving access to treatment options in areas with unmet needs.

What is ARESTIN?
ARESTIN® (minocycline HCl) Microspheres, 1mg is used in combination with scaling and root planing (SRP) procedures to treat patients with adult periodontitis (gum disease). ARESTIN® may be used as part of an overall oral health program that includes good brushing and flossing habits and SRP.

IMPORTANT SAFETY INFORMATION

• Do not use ARESTIN if you are allergic to minocycline or tetracyclines, ask your dentist if you are not sure. Do not use ARESTIN in children, pregnant or nursing women as the use of tetracycline class drugs, including ARESTIN, during tooth development may cause permanent discoloration of the teeth.
• ARESTIN may cause you to be sensitive to sunlight. Patients exposed to direct sunlight or ultraviolet light may develop a severe sunburn. At the first evidence of skin redness, call your dentist.
• Serious allergic reactions have occurred with oral minocycline. Get emergency help right away if you experience any signs of an allergic reaction including shortness of breath, swelling of the face, throat and tongue, rash, hives, itching, fever, or enlarged lymph nodes.
• Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes with symptoms such as joint pain, muscle pain, rash, swelling, fever, enlarged lymph nodes, and general body weakness.
• Tell your dentist about all the medicines you take, and about any health problems you have, including if you've had oral candidiasis ("thrush").
• ARESTIN has not been studied in patients with weakened immune systems, such as patients with HIV infections or diabetes, or those receiving chemotherapy or radiation.
• The most frequently reported non-dental side effects were headache, infection, flu symptoms, and pain.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. OraPharma is a specialty pharmaceutical company committed to partnering with dental professionals to improve oral health. More information can be found at www.orapharma.com. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.

Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

REFERENCE:
⁽¹⁾ Hu M, Zhang R, Wang R, Wang Y, Guo J. Global, regional, and national burden of periodontal diseases from 1990 to 2021 and predictions to 2040: an analysis of the Global Burden of Disease Study 2021. Front Oral Health. 2025;6:1627746. doi:10.3389/froh.2025.1627746. [frontiersin.org]

ARESTIN is a trademark Bausch Health Companies Inc. or its affiliates.
© 2026 Bausch Health Companies Inc. or its affiliates.

Investor Contact:	Media Contact:
Garen Sarafian	Katie Savastano
ir@bauschhealth.com	corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)	(908) 569-3692
BHC- PRODUCTS

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-healths-orapharma-celebrates-25-years-of-arestin--minocycline-hcl-microspheres-302691824.html

SOURCE Bausch Health Companies Inc.

FAQ

What is ARESTIN and how is it used with SRP by BHC (NYSE:BHC)?

ARESTIN is a locally applied 1 mg minocycline microsphere used as an adjunct to SRP for adult periodontitis. According to Bausch Health, it delivers antibiotic directly into the periodontal pocket and biodegrades while releasing drug over time to reduce pocket depth.

What does Bausch Health's 25th anniversary of ARESTIN (BHC) signify for clinicians?

The 25th anniversary highlights long clinical use and FDA approval as a targeted adjunctive therapy. According to Bausch Health, it reflects sustained adoption by dental professionals and continued focus on non‑surgical periodontal treatment and clinician collaboration.

Has Bausch Health expanded ARESTIN availability recently (NYSE:BHC)?

Yes, OraPharma has expanded ARESTIN commercially into Canada and Puerto Rico to improve access. According to Bausch Health, these expansions are intended to reach areas with unmet treatment needs for periodontal care.

Who should not use ARESTIN according to Bausch Health (BHC)?

ARESTIN should not be used by people allergic to minocycline or tetracyclines, or by children, pregnant or nursing women. According to Bausch Health, tetracyclines can cause permanent tooth discoloration during tooth development.

What are the common side effects and safety warnings for ARESTIN (BHC)?

Common non‑dental side effects include headache, infection, flu symptoms, and pain. According to Bausch Health, serious allergic reactions and photosensitivity are possible and patients should seek emergency care for severe symptoms.

How does ARESTIN work in the periodontal pocket, per Bausch Health (NYSE:BHC)?

ARESTIN uses biodegradable microspheres that slowly release minocycline directly in the periodontal pocket over time. According to Bausch Health, this targeted delivery aims to reduce pocket depth when used with scaling and root planing.